Metformin's Anti-Diabetic Effects Linked to Brain Mechanism Involving Rap1 Protein
核心洞察
Researchers at Baylor College of Medicine discovered that metformin works by targeting the Rap1 (搜索) protein in the brain's ventromedial hypothalamus to control blood sugar levels.
Mouse studies showed that metformin failed to lower blood glucose in genetically modified animals lacking Rap1 (搜索), while other diabetes treatments remained effective.
The findings suggest metformin's therapeutic effects extend beyond liver and gut mechanisms, opening possibilities for new brain-targeted diabetes treatments.
Metformin, prescribed to approximately 120 million people worldwide for type 2 diabetes (搜索) management, exerts its anti-diabetic effects through a previously unknown brain mechanism involving the Rap1 (搜索) protein, according to new research from Baylor College of Medicine published in 2025.
The study, led by pathophysiologist Dr. Makoto Fukuda, challenges the conventional understanding of how this 60-year-old medication works. "It's been widely accepted that Metformin lowers blood glucose primarily by reducing glucose output in the liver. Other studies have found that it acts through the gut," said Dr. Fukuda, Associate Professor of Paediatrics-Nutrition at Baylor. "We looked into the brain as it is widely recognized as a key regulator of whole-body glucose metabolism."
Brain-Specific Mechanism Discovered
The research team identified that metformin targets the ventromedial hypothalamus (VMH), a brain region crucial for energy and glucose regulation. Within this area, the drug specifically inhibits the Rap1 (搜索) protein, which plays a key role in whole-body glucose metabolism. When metformin reaches the brain, it activates SF1 neurons (搜索), thereby regulating energy and sugar utilization throughout the body.
To validate this mechanism, researchers conducted experiments using genetically modified mice lacking the Rap1 (搜索) protein in the VMH. These animals were fed a high-fat diet to simulate type 2 diabetes (搜索) conditions. The results demonstrated that metformin failed to reduce blood sugar levels in mice without Rap1, while other diabetes treatments including insulin and GLP-1 agonists (搜索) (the same drug family as Ozempic) remained effective.
Direct Brain Administration Shows Potent Effects
Further experiments revealed the potency of this brain-mediated pathway. When researchers directly injected metformin into the brains of mice, they observed significant blood sugar reduction using doses much smaller than those required for oral administration. This finding underscores the importance of the brain mechanism in metformin's overall therapeutic effect.
"This discovery changes how we think about metformin. It's not just working in the liver or the gut, it's also acting in the brain," Dr. Fukuda explained.
Implications for Future Treatments
The identification of this brain-specific pathway opens new avenues for diabetes treatment development. "These findings open the door to developing new diabetes treatments that directly target this pathway in the brain," Dr. Fukuda noted.
Beyond glucose control, metformin is recognized for additional health benefits, including potential brain aging deceleration, DNA protection, and activation of longevity-associated genes. The research team plans to investigate whether the same brain Rap1 (搜索) signaling mechanism underlies these other documented effects.
Safety Profile Remains Consistent
Despite this new understanding of metformin's mechanism, its safety profile remains unchanged. The medication continues to be generally well-tolerated, though gastrointestinal side effects including nausea, diarrhea, and abdominal discomfort affect up to 75% of users. Patients with kidney problems may face higher risks and require careful monitoring.
The discovery represents a significant advancement in understanding how this widely prescribed medication achieves its therapeutic effects, potentially leading to more targeted and effective diabetes treatments in the future.